Feedback
The current prices are delayed. Login to see live prices.

Caplin Point Laboratories Ltd.

(CAPLIPOINT)

20123456789,001234567890012345678940123456789.1012345678950123456789
-115.45 (-5.45%)
Updated 16:03 06/09 IST
Add
1D
5D
1M
3M
1Y
5Y
MAX
Previous Close: 2119.6
Today's low
₹1,987.15
Today's high
₹2,144
52 week low
₹954
52 week high
₹2,158.8
Open
₹2,085
Prev Close
₹2,119.6
Volume (shares)
667,963
Total Trading Value
141.58 Cr

Technicals

SMA
Value
Signal
12-SMA
1,898.37
Bullish
20-SMA
1,797.01
Bullish
50-SMA
1,625.44
Bullish
100-SMA
1,482.3
Bullish
200-SMA
1,425.69
Bullish

Valuations

PE Chart
303540455055
Median PE (M) : 36.53
Current PE is higher than median PE.
PB Chart
4.05.06.0
Median PB (M) : 4.2
Current PB is higher than median PB.

Fundamentals

Market Cap
₹15,231.54 Cr
Enterprise Value
₹14,741.47 Cr
No. of Shares
7.6 Cr
P/E Ratio(TTM)
31.89
RoE
23.68%
Debt/Equity
0
Revenue vs Profitability (In Cr.)
0.20.40.60.81.01.21.41.6
Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Revenue
Profit
Margins (%)
253035
Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Gross Margin
Net Margin

Ratios

Debt/Equity
0.0000.0100.0200.0300.040
Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Debt to Equity
ROE vs ROCE
2224262830323436
Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE
ROCE

Shareholding

Shareholding Pattern
Public : 24.57%
FII : 3.37%
Others : 0%
DII : 1.49%
Promoter : 70.56%
Shareholding History
2.42.62.83.03.2
Mar, 2023Jun, 2023Sep, 2023Dec, 2023Mar, 2024Jun, 2024

Peer Comparison

Peer companies
Market Capital (Cr.)
P/E
P/B
Price(₹)
SUNPHARMA
437,482.74
42.14
18.29
1,826.5
GRANULES
16,671.33
33.89
5.23
698.2
NEULANDLAB
16,551.26
49.27
12.05
12,769.15
WOCKPHARMA
15,871.75
0
8.87
1,089
CAPLIPOINT
15,250.23
31.89
10.41
2,119.6
JUBLPHARMA
15,161.97
27.42
6.44
937.7
GLS
14,085.28
31.54
5.79
1,093

Discussions

  •  Sep 5 4:08 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Caplin Point Laboratories shares jumped almost 10 perc...read more

  •  Aug 19 7:36 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Caplin Steriles' injectable and ophthalmic manufacturi...read more

  •  Aug 19 7:25 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Caplin Labs reported a 16.1% increase in net sales and a 19.86% in...read more

  •  Aug 19 5:58 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Caplin Point Labs' shares jumped over 13% to a 52-week...read more

  •  Aug 18 4:49 AM
ANVISA-Brazil concludes inspection at manufacturing facility of Caplin Point’s arm...read more

1

  •  Aug 11 4:50 AM
USFDA completes unannounced inspection at Caplin Point’s arm’s manufacturing facility in Tamil Nadu...read more

2

  •  Aug 9 4:50 AM
Caplin Point Lab - Quarterly Results
Earnings Update...read more

  •  Aug 9 4:50 AM
Caplin Point Laboratories’ arm gets USFDA’s final nod for Timolol Maleate Ophthalmic Solution...read more

  •  Aug 8 9:04 PM
𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Caplin Labs reported a 6.9% increase in net sales in June 2024 com...read more

  •  Aug 6 12:30 AM
#CAPLIPOINT will declare results on Aug 7, 2024
Please plan your trades accordingly 😎

  •  Aug 3 12:17 PM
CUP pattern breakout

18

4
4
  •  Jul 20 4:47 AM
Caplin Point Laboratories’ arm gets USFDA’s approval for Ephedrine Sulfate Injection...read more

1
  •  Jul 14 7:55 PM
#CAPLIPOINT for education
swing trade...read more

1

Load More Posts

Frequently Asked Questions (FAQs)

What is the Share Price of Caplin Point Laboratories Ltd. ?

The share prices are volatile and fluctuate throughout the trading hours. The share price of Caplin Point Laboratories Ltd. is Rs 2119.6 as of 06 September 2024.

What is the Market Capitalization of Caplin Point Laboratories Ltd. ?

The current market cap of Caplin Point Laboratories Ltd. is ₹15231.54 Cr. Market capitalisation is calculated by multiplying the current share price with the total number of shares.

What are the PE and PB ratios of Caplin Point Laboratories Ltd.?

Caplin Point Laboratories Ltd. has a price-to-earnings (PE) ratio of 31.89 and a price-to-book (PB) ratio of 6.24.

What is the 52-week high/low of Caplin Point Laboratories Ltd.?

The 52-week high of Caplin Point Laboratories Ltd. is Rs 2158.8 and the 52-week low is Rs 954
Hero Img
Join 10,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Create your account on Frontpage
DisclaimerPrivacy
FrontPage © 2024